Fortress Biotech (FBIO): 3 Positive Takeaways from AstraZeneca's Deal to Acquire Caelum - Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Jennifer Kim reiterated an Overweight rating and $6.00 price target on Fortress Biotech (NASDAQ: FBIO) after AstraZeneca's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
